1-(7,8-dihydro-8,8-dimethyl-5-phenyl-naphthalen-2-yl)-ethan-1-one | 188889-66-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(7,8-dihydro-8,8-dimethyl-5-phenyl-naphthalen-2-yl)-ethan-1-one
• 英文别名: 3,4-dihydro-1-phenyl-4,4-dimethyl-6-acetylnaphthalene；1-(8,8-dimethyl-5-phenyl-7H-naphthalen-2-yl)ethanone
• CAS: 188889-66-9
• 化学式: C₂₀H₂₀O
• 分子量: 276.378
• InChiKey: ZDKLNUGPSIBBIB-UHFFFAOYSA-N

物化性质

• 熔点：
  71 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
• 沸点：
  415.3±44.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(7,8-dihydro-8,8-dimethyl-5-phenyl-naphthalen-2-yl)-ethan-1-one 、 4-甲酰基苯甲酸乙酯 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 甲醇 为溶剂， 反应 15.0h， 以63%的产率得到4-[(1E)-3-(7,8-dihydro-8,8-dimethyl-5-phenylnaphthalen-2-yl)-3-oxoprop-1-en-1-yl]-benzoic acid
  参考文献：
  名称：

  Retinoid receptor subtype-selective modulators through synthetic modifications of RARγ agonists

  摘要：

  A series of retinoids designed to interfere with the repositioning of H12 have been synthesized to identify novel RAR gamma antagonists based on the structure of known RAR gamma agonists. The transcriptional activities of the novel ligands were revealed by cell-based reporting assays, using engineered cells containg RAR subtype-selective fusions of the RAR ligand-binding domains with the yeast GAL4 activator DNA-binding domain and the cognate luciferase reporter gene. Whereas none of the ligands exhibited features of a selective RAR gamma antagonist, some of them are endowed with interesting activities. In particular 24a acts as a pan-RAR agonist that induces at high concentration a higher transactivation potential on RAR alpha than TTNPB and synergizes at low concentration with TTNPB-bound RAR alpha but not RAR beta or RAR gamma. Similarly, 24c synergizes with TTNPB-bound RAR gamma and exhibits RAR alpha,beta antagonist activity. Compounds 24b and 25b are strong RAR alpha,beta-selective antagonists without agonist or antagonist activities for RAR gamma. Compounds 24b and 24c display weak RXR antagonist activity. In addition several pan-antagonists and partial agonist/antagonists have been defined. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.035
• 作为产物：
  描述：

  1-(7,8-dihydro-8,8-dimethyl-5-phenyl-naphthalen-2-yl)-ethan-2-ol 在 manganese(IV) oxide 、 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以99%的产率得到1-(7,8-dihydro-8,8-dimethyl-5-phenyl-naphthalen-2-yl)-ethan-1-one
  参考文献：
  名称：

  Retinoid receptor subtype-selective modulators through synthetic modifications of RARγ agonists

  摘要：

  A series of retinoids designed to interfere with the repositioning of H12 have been synthesized to identify novel RAR gamma antagonists based on the structure of known RAR gamma agonists. The transcriptional activities of the novel ligands were revealed by cell-based reporting assays, using engineered cells containg RAR subtype-selective fusions of the RAR ligand-binding domains with the yeast GAL4 activator DNA-binding domain and the cognate luciferase reporter gene. Whereas none of the ligands exhibited features of a selective RAR gamma antagonist, some of them are endowed with interesting activities. In particular 24a acts as a pan-RAR agonist that induces at high concentration a higher transactivation potential on RAR alpha than TTNPB and synergizes at low concentration with TTNPB-bound RAR alpha but not RAR beta or RAR gamma. Similarly, 24c synergizes with TTNPB-bound RAR gamma and exhibits RAR alpha,beta antagonist activity. Compounds 24b and 25b are strong RAR alpha,beta-selective antagonists without agonist or antagonist activities for RAR gamma. Compounds 24b and 24c display weak RXR antagonist activity. In addition several pan-antagonists and partial agonist/antagonists have been defined. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.035

文献信息

• Synthesis and use of retinoid compounds having negative hormone and/or
  申请人：Allergan Sales, Inc.

  公开号：US05877207A1

  公开（公告）日：1999-03-02

  Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

  芳基取代和芳基和（3-氧代-1-丙烯基）取代的苯并吡喃、苯并硫吡喃、1,2-二氢喹啉和5,6-二氢萘衍生物具有视黄醇负性激素和/或拮抗剂样生物活性。所发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减轻RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂可与视黄醇药物一起给予或联合给予，以防止或减轻视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醇负性激素可用于增强其他视黄醇和核受体激动剂的活性。例如，名为AGN 193109的视黄醇负性激素在体外转录激活实验中有效增加了其他视黄醇和类固醇激素的效力。此外，转录激活实验可用于识别具有负性激素活性的化合物。这些实验基于负性激素调节具有构成转录激活子结构域的嵌合视黄醇受体活性的能力。
• [EN] BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY<br/>[FR] DERIVES DE BENZOPYRANE ET BENZOTHYOPYRANE PRESENTANT UNE ACTIVITE RETINOÏDE DE TYPE ANTAGONISTE
  申请人：ALLERGAN SALES, INC.

  公开号：WO1999033821A1

  公开（公告）日：1999-07-08

  (EN) 2,2-Dialkyl- 4-aryl-substituted benzopyran and benzothiopyran derivatives of formula (I) where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action or RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.(FR) L'invention concerne des dérivés de 2,2-dialkyl-benzopyrane et benzothiopyrane à substitution 4-aryl de formule (I), dont les symboles sont définis dans le descriptif. Ces dérivés présentent des activités biologiques rétinoïdes de type antagonistes et/ou hormones négatives. Les antagonistes de RAR de l'invention peuvent être administrés aux mammifères, y compris aux humains, pour prévenir ou réduire l'action d'antagonistes de RAR sur les sites récepteurs liés. En particulier, les agonistes de RAR sont administrés ou co-administrés avec des médicaments rétinoïdes pour empêcher ou atténuer la toxicité ou les effets secondaires des rétinoïdes, de la vitamine A ou des précurseurs de la vitamine A. Les hormones négatives rétinoïdes peuvent être utilisées pour renforcer les activités d'autres rétinoïdes et celles d'agonistes de récepteurs nucléaires.

  2,2-二烷基-4-芳基取代苯并吡喃和苯并噻吩的衍生物，其化学式为(I)，其中符号的含义在说明书中描述，具有视黄醇负性激素和/或拮抗剂样生物活性。发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减少RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂与视黄醇药物一起给予或联合给予，以防止或缓解视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醇负性激素可用于增强其他视黄醇和核受体激动剂的活性。
• Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
  申请人：——

  公开号：US20030219832A1

  公开（公告）日：2003-11-27

  Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

  取代芳基和取代芳基和（3-氧代-1-丙烯基）基苯并吡喃、苯并硫吡喃、1,2-二氢喹啉和5,6-二氢萘衍生物具有视黄醛受体负性激素和/或拮抗剂样的生物活性。发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减少RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂与视黄醇药物一起使用或联合使用，以防止或缓解视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醛负性激素可用于增强其他视黄醇和核受体激动剂的活性。例如，名为AGN 193109的视黄醛负性激素在体外转录激活测定中有效地增加了其他视黄醇和类固醇激素的效力。此外，转录激活测定可用于鉴定具有负性激素活性的化合物。这些测定基于负性激素降调节嵌合视黄醛受体活性的能力。
• Method of identifying negative hormone and/or antagonist activities
  申请人：Allergan, Inc.

  公开号：US05776699A1

  公开（公告）日：1998-07-07

  Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

  取代芳基和芳基和(3-氧代-1-丙烯基)-取代苯并吡喃、苯并硫喹啉、1,2-二氢喹啉和5,6-二氢萘衍生物具有视黄酸负性激素和/或拮抗剂样生物活性。发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减少RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂与视黄酸药物一起或同时投与，以防止或减轻由视黄酸或视黄酸前体引起的毒性或副作用。视黄酸负性激素可用于增强其他视黄酸和核受体激动剂的活性。例如，名为AGN 193109的视黄酸负性激素在体外转录激活实验中有效增强了其他视黄酸和类固醇激素的效果。此外，转录激活实验可用于鉴定具有负性激素活性的化合物。这些实验基于负性激素通过下调带有组成性转录激活子域的嵌合视黄酸受体的活性的能力。
• US5958954
  申请人：——

  公开号：——

  公开（公告）日：——